What do systematic reviews say?

Paroxetine vs aprepitant

• Paroxetine versus other anti‐depressive agents for depression 2014 · Cochrane Headline outcomes only
  no estimate extracted
  0 studies · 0 participants
  GRADE not reported

Paroxetine vs older ADs

Paroxetine showed no clear difference in failure to respond at endpoint (6‐12 weeks) compared with older ADs (moderate certainty).

• Paroxetine versus other anti‐depressive agents for depression 2014 · Cochrane Headline outcomes only
  OR 1.04 [0.92, 1.17]
  34 studies · 4647 participants
  Moderate

Paroxetine vs sertraline

Paroxetine showed no clear difference in failure to respond at endpoint (6‐12 weeks) compared with sertraline (moderate certainty).

• Paroxetine versus other anti‐depressive agents for depression 2014 · Cochrane Headline outcomes only
  OR 1.25 [0.89, 1.77]
  3 studies · 618 participants
  Moderate

Paroxetine vs tianeptine

Paroxetine showed no clear difference in failure to respond at endpoint (6‐12 weeks) compared with tianeptine (moderate certainty).

• Paroxetine versus other anti‐depressive agents for depression 2014 · Cochrane Headline outcomes only
  OR 1.04 [0.71, 1.53]
  3 studies · 648 participants
  Moderate

Paroxetine vs trazodone

Paroxetine showed no clear difference in failure to respond at endpoint (6‐12 weeks) compared with trazodone (moderate certainty).

• Paroxetine versus other anti‐depressive agents for depression 2014 · Cochrane Headline outcomes only
  OR 0.71 [0.21, 2.41]
  1 study · 108 participants
  Moderate

Paroxetine vs venlafaxine

Paroxetine showed no clear difference in failure to respond at endpoint (6‐12 weeks) compared with venlafaxine (low certainty).

• Paroxetine versus other anti‐depressive agents for depression 2014 · Cochrane Headline outcomes only
  OR 1.1 [0.58, 2.11]
  4 studies · 747 participants
  Low

Paroxetine vs AMISULPRIDE

Paroxetine showed no clear difference in failure to respond at endpoint (6‐12 weeks) compared with amisulpride (moderate certainty).

• Paroxetine versus other anti‐depressive agents for depression 2014 · Cochrane Headline outcomes only
  OR 0.65 [0.36, 1.15]
  1 study · 277 participants
  Moderate

Paroxetine vs bupropion

Paroxetine showed no clear difference in failure to respond at endpoint (6‐12 weeks) compared with bupropion (moderate certainty).

• Paroxetine versus other anti‐depressive agents for depression 2014 · Cochrane Headline outcomes only
  OR 0.73 [0.3, 1.79]
  1 study · 100 participants
  Moderate

Paroxetine vs citalopram

Paroxetine probably leads to higher failure to respond at endpoint (6‐12 weeks) compared with citalopram (moderate certainty).

• Paroxetine versus other anti‐depressive agents for depression 2014 · Cochrane Headline outcomes only
  OR 1.54 [1.04, 2.28]
  1 study · 406 participants
  Moderate

Paroxetine vs duloxetine

Paroxetine showed no clear difference in failure to respond at endpoint (6‐12 weeks) compared with duloxetine (moderate certainty).

• Paroxetine versus other anti‐depressive agents for depression 2014 · Cochrane Headline outcomes only
  OR 0.89 [0.7, 1.14]
  6 studies · 1821 participants
  Moderate

Paroxetine vs escitalopram

Paroxetine showed no clear difference in failure to respond at endpoint (6‐12 weeks) compared with escitalopram (moderate certainty).

• Paroxetine versus other anti‐depressive agents for depression 2014 · Cochrane Headline outcomes only
  OR 1.12 [0.76, 1.65]
  2 studies · 784 participants
  Moderate

Paroxetine vs fluoxetine

Paroxetine showed no clear difference in failure to respond at endpoint (6‐12 weeks) compared with fluoxetine (moderate certainty).

• Paroxetine versus other anti‐depressive agents for depression 2014 · Cochrane Headline outcomes only
  OR 1.98 [0.79, 1.23]
  11 studies · 2418 participants
  Moderate

Paroxetine vs fluvoxamine

Paroxetine showed no clear difference in failure to respond at endpoint (6‐12 weeks) compared with fluvoxamine (moderate certainty).

• Paroxetine versus other anti‐depressive agents for depression 2014 · Cochrane Headline outcomes only
  OR 1.19 [0.72, 1.94]
  3 studies · 261 participants
  Moderate

Paroxetine vs hypericum

Paroxetine showed no clear difference in failure to respond at endpoint (6‐12 weeks) compared with hypericum (moderate certainty).

• Paroxetine versus other anti‐depressive agents for depression 2014 · Cochrane Headline outcomes only
  OR 1.6 [0.95, 2.69]
  1 study · 251 participants
  Moderate

Paroxetine vs milnacipran

Paroxetine showed no clear difference in failure to respond at endpoint (6‐12 weeks) compared with milnacipran (moderate certainty).

• Paroxetine versus other anti‐depressive agents for depression 2014 · Cochrane Headline outcomes only
  OR 0.93 [0.59, 1.47]
  1 study · 302 participants
  Moderate

Paroxetine vs agomelatine

Paroxetine showed no clear difference in failure to respond at endpoint (6‐12 weeks) compared with agomelatine (moderate certainty).

• Paroxetine versus other anti‐depressive agents for depression 2014 · Cochrane Headline outcomes only
  OR 1.25 [0.78, 2.01]
  1 study · 284 participants
  Moderate

Paroxetine vs mirtazapine

Paroxetine showed no clear difference in failure to respond at endpoint (6‐12 weeks) compared with mirtazapine (moderate certainty).

• Paroxetine versus other anti‐depressive agents for depression 2014 · Cochrane Headline outcomes only
  OR 1.2 [0.9, 1.61]
  4 studies · 766 participants
  Moderate

Paroxetine vs nefazodone

Paroxetine showed no clear difference in failure to respond at endpoint (6‐12 weeks) compared with nefazodone (moderate certainty).

• Paroxetine versus other anti‐depressive agents for depression 2014 · Cochrane Headline outcomes only
  OR 0.31 [0.07, 1.25]
  1 study · 40 participants
  Moderate

Paroxetine vs reboxetine

Paroxetine showed no clear difference in failure to respond at endpoint (6‐12 weeks) compared with reboxetine (moderate certainty).

• Paroxetine versus other anti‐depressive agents for depression 2014 · Cochrane Headline outcomes only
  OR 0.82 [0.66, 1.02]
  3 studies · 1369 participants
  Moderate